Platform for efficient development of innovative anti-cancer therapies
Torqur is a Swiss clinical-stage biotech company launched in 2021 as a subsidiary of Swiss Rockets, a Basel-based incubator and accelerator of start-up companies in oncology and infectiology.
LEARN MOREFulfil patients' expectations through precise science.
Each cancer treatment remains a case-by-case battle, with a limited panel of therapeutic options available. Considering the relatively low response of cancer patients to standards of care that are effective only in a narrow subset of patients, there is a tremendous need for new targeted therapies.
LEARN MOREStrategy
Research and development experts at Torqur aim to create a portfolio of disease-specific mTOR and/or PI3K inhibitors with optimized pharmacokinetic and safety properties. By employing the most promising molecules designed to specifically inhibit desired pathways of cancer cells and minimize possible drug toxicity, Torqur intends to turn cancer into a manageable disease.
LEARN MORETECHNOLOGY
The PI3K/Akt/mTOR pathway is one of the major cellular pathways that plays a key role in basic intracellular functions including cell growth, proliferation, motility, differentiation, and survival. Disruption and abnormal activation of the PI3K/Akt/mTOR pathway are frequently observed in various human malignancies making this pathway an attractive therapeutic target in the treatment of cancer.
LEARN MORE
Prof. Dr. Michael N. Hall
Chairman and Non-Executive Board MemberProf. Dr. Michael N. Hall is an American and Swiss molecular biologist and Professor at the Biozentrum of the University of Basel. He earned a Ph.D. in Molecular Genetics from Harvard University in 1981 and was a postdoctoral fellow at the Institut Pasteur in Paris and the University of California, San Francisco.
READ MORE
Dr. Vladimir Cmiljanovic
Vice-Chairman and Executive Board MemberDr. Vladimir Cmiljanovic is a renowned serial biotech entrepreneur, cancer scientist, and medicinal chemist with over 15 years of experience in oncology drug development.
READ MORE
Dr. Natasa Cmiljanovic
Executive Board MemberDr. Natasa Cmiljanovic is a dynamic and accomplished professional, serving as the Chief Operating Officer and Founder of Swiss Rockets. With over a decade of invaluable experience in oncology drug development, Natasa's background as a medicinal chemist and clinical scientist makes her a driving force in the field.
READ MORE
Dr. Jeanette Wood
Non-Executive Board MemberDr. Jeanette Wood is an accomplished scientist with extensive experience in all aspects of drug discovery across multiple disease areas, including cancer.
READ MORE
Dr. Thomas Ladner
Non-Executive Board Member & SecretaryDr. Thomas Ladner, Board Member and Secretary of the Board, became in 2002 the youngest partner at Meyerlustenberger Lachenal, one of Switzerland's leading law firms, where he specialized in private equity and M&A. From 2000 to 2004, Thomas lectured on corporate law and contract law at the University of St. Gallen (Switzerland), from where he also holds a Ph.D.
READ MORE
Christoph Tschumi
Non-Executive Board MemberChristoph Tschumi is a senior business consultant with a focus on organisational development, governance, as well as economic analysis and risk management. He is member of various boards. In the Foundation Board of the Basel Institute on Governance, as well as the board of Pension Fund of the Canton Basel-Stadt he is head of the finance and audit committees.
READ MORE
Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)
10 September 2024
LEARN MORE
Torqur AG Announces First Patient Dosed in Phase 2 Clinical Trial of Bimiralisib in Actinic Keratosis
15 April 2024
LEARN MORE
Swiss Biotech TORQUR AG Unveils Groundbreaking Data on New Cancer Drug Candidate Bimiralisib
20 March 2024
LEARN MORE
Swiss Rockets AG and its subsidiary Torqur AG welcome four key scientific members
20 September 2023
LEARN MORE
